<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364648">
  <stage>Registered</stage>
  <submitdate>25/07/2013</submitdate>
  <approvaldate>1/08/2013</approvaldate>
  <actrnumber>ACTRN12613000846729</actrnumber>
  <trial_identification>
    <studytitle>Sevoflurane for maintenance of anaesthesia in major vascular surgery: using the bispectral index to determine the minimum alveolar concentration</studytitle>
    <scientifictitle>Minimum alveolar concentration of sevoflurane to maintain bispectral index below 50 in major vascular surgery</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>bispectral index guided minimum alveolar concentration of sevoflurane for maintenance of anaesthesia in major vascular surgery </healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>ASA physical status I and II patients scheduled to undergo major vascular surgery are enrolled in this study. Monitoring consists on blood pressure, heart rate, pulse oxymetry, endtidal CO2, entidal sevoflurane and bispectral index.

Induction of anaesthesia is standardized in all patients using target controlled infusion of propofol and remifentanil. Muscle relaxation is achieved with cisatracurium.

After tracheal intubation, propofol infusion is stopped. When the bispectral index reach 65 sevoflurane inhalation is started at the predetermined concentration. The predetermined endtidal concentration for the first patient is 2%. Sevoflurane is used once only to maintain anaesthesia.

The endtidal sevoflurane concentration is adjusted with starting dose of 2% for the first patient and maintained for 10 min to ensure equilibration with the cerebral anesthetic partial pressure followed by assessment of BIS. In the next patients doses are given according to the following rule: if the subject responds positively (BIS&lt;50 after 10 minutes of sevoflurane), the endtidal concentration is decreased by 0.2% step for the next subject, and conversely, if the subject does not respond (BIS&gt;50 after 10 minutes of sevoflurane), the dose is increased by 0.2% step.  
The ED50 and ED95 of sevoflurane to maintain bispectral index below 50 are calculated using probit transformation. </interventions>
    <comparator>Not applicable </comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>the bispectral index value after the exposure to a predetermined alveolar concentration of sevoflurane </outcome>
      <timepoint>10 minutes after reaching the predetermined end expiratory concentration of sevoflurane</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Variation of blood pressure using invasive or non invasive monitoring as required and heart rate using ECG monitoring during exposure to sevoflurane </outcome>
      <timepoint>Every minute during the first 10 minutes of exposure to sevoflurane</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>ASA I or II adults scheduled to undergo major vascular surgery under general anaesthesia</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known allergy to sevoflurane
Previous renal disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures>Up and down design </designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>We fixed the sample size according to the three previous studies that all used 20 participants. </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>6/05/2013</anticipatedstartdate>
    <actualstartdate>6/05/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>25/07/2013</actualenddate>
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Tunisia</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Military Hospital of Tunis</primarysponsorname>
    <primarysponsoraddress>Montfleury
1089 Tunis</primarysponsoraddress>
    <primarysponsorcountry>Tunisia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Military Hospital of Tunis</fundingname>
      <fundingaddress>Montfleury
1089 Tunis</fundingaddress>
      <fundingcountry>Tunisia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aim to determine the minimum alveolar concentration of sevoflurane to maintain the bispectral index below 50 in 95% of patients undergoing major vascular surgery. This will permit to better choose sevoflurane concentration that allow an adequate anaesthesia with a minimal risk of memorisation even when bispectral index is unavailable.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Military Hospital of Tunis Local Ethics Committee</ethicname>
      <ethicaddress>Montfleury
1089 Tunis</ethicaddress>
      <ethicapprovaldate>17/04/2013</ethicapprovaldate>
      <hrec>043/013</hrec>
      <ethicsubmitdate />
      <ethiccountry>Tunisia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Radhouane Bousselmi</name>
      <address>Military Hospital of Tunis
15 avenue de la Republique
2000 Bardo</address>
      <phone>+216 22 622 495</phone>
      <fax />
      <email>rdh.bousselmi@gmail.com</email>
      <country>Tunisia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Radhouane Bousselmi</name>
      <address>Military Hospital of Tunis
15 avenue de la Republique
2000 Bardo</address>
      <phone>+216 22 622 495</phone>
      <fax />
      <email>rdh.bousselmi@gmail.com</email>
      <country>Tunisia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Radhouane Bousselmi</name>
      <address>Military Hospital of Tunis
15 avenue de la Republique
2000 Bardo</address>
      <phone>+216 22 622 495</phone>
      <fax />
      <email>rdh.bousselmi@gmail.com</email>
      <country>Tunisia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>